ReproCELL Incorporated
ReproCELL Incorporated provides stem cell research and drug discovery services in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, feeder ce… Read more
Market Cap & Net Worth: ReproCELL Incorporated (6RC)
ReproCELL Incorporated (F:6RC) has a market capitalization of $69.98 Million (€68.17 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #19849 globally and #2117 in its home market, demonstrating a -4.64% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ReproCELL Incorporated's stock price €0.72 by its total outstanding shares 94685635 (94.69 Million).
ReproCELL Incorporated Market Cap History: 2015 to 2026
ReproCELL Incorporated's market capitalization history from 2015 to 2026. Data shows change from $262.90 Million to $69.98 Million (-13.42% CAGR).
ReproCELL Incorporated Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ReproCELL Incorporated's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.02x
ReproCELL Incorporated's market cap is 0.02 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.54x
ReproCELL Incorporated's market cap is 0.54 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $335.22 Million | $1.07 Billion | -$1.96 Billion | 0.31x | N/A |
| 2017 | $227.14 Million | $1.26 Billion | -$911.66 Million | 0.18x | N/A |
| 2018 | $144.82 Million | $926.25 Million | -$2.17 Billion | 0.16x | N/A |
| 2019 | $166.20 Million | $1.09 Billion | -$601.42 Million | 0.15x | N/A |
| 2020 | $309.07 Million | $1.20 Billion | -$1.02 Billion | 0.26x | N/A |
| 2021 | $173.00 Million | $1.29 Billion | -$812.57 Million | 0.13x | N/A |
| 2022 | $206.05 Million | $2.23 Billion | -$575.09 Million | 0.09x | N/A |
| 2023 | $88.93 Million | $2.95 Billion | -$305.31 Million | 0.03x | N/A |
| 2024 | $41.99 Million | $2.43 Billion | -$31.41 Million | 0.02x | N/A |
| 2025 | $55.40 Million | $2.98 Billion | $103.25 Million | 0.02x | 0.54x |
Competitor Companies of 6RC by Market Capitalization
Companies near ReproCELL Incorporated in the global market cap rankings as of March 19, 2026.
Key companies related to ReproCELL Incorporated by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
ReproCELL Incorporated Historical Marketcap From 2015 to 2026
Between 2015 and today, ReproCELL Incorporated's market cap moved from $262.90 Million to $ 69.98 Million, with a yearly change of -13.42%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €69.98 Million | +26.32% |
| 2025 | €55.40 Million | +31.94% |
| 2024 | €41.99 Million | -52.79% |
| 2023 | €88.93 Million | -56.84% |
| 2022 | €206.05 Million | +19.10% |
| 2021 | €173.00 Million | -44.03% |
| 2020 | €309.07 Million | +85.96% |
| 2019 | €166.20 Million | +14.77% |
| 2018 | €144.82 Million | -36.24% |
| 2017 | €227.14 Million | -32.24% |
| 2016 | €335.22 Million | +27.50% |
| 2015 | €262.90 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of ReproCELL Incorporated was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $69.98 Million USD |
| MoneyControl | $69.98 Million USD |
| MarketWatch | $69.98 Million USD |
| marketcap.company | $69.98 Million USD |
| Reuters | $69.98 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.